[ad_1]
Fosun Pharma (02196) announced that Fosun Pharma, Fosun New Drug, Fuhong Hanlin and other existing shareholders, as well as investors, have entered into a capital increase agreement.
According to the agreement, Fuhong Hanlin issued a total of 25.12 million shares of Xinfu Honghanlin at a price of 6.23 dollars per share, a total consideration of about 157 million yuan. U.S. dollars. At the same time, according to the agreement, the industry Fosun Pharma and Fosun New Drug will make no contribution to Fuhong Hanlin.
After the completion of the transaction, the shares of Fuhong Hanlin Corporation, owned by Fosun Pharma and Fosun New Drugs, will be reduced from approximately 64.51% to approximately 61.09%. Therefore, the operation under the terms of the capital increase agreement will constitute a 3.42% stake in Fuhong Hanlin held by the company as a sale.
The company said that in order to meet the needs of research and development and operations, and further consolidate its leading position in the field of research and development of monoclonal antibody drugs, Fuhong Hanlin intends to increase the capital.
[ad_2]
Source link
